FibroGen, Inc

FibroGen, Inc we work at the intersection of pioneering science and patient need. Our research and development teams seek to identify and develop innovative drugs with the greatest promise of becoming first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, and pancreatic cancer. Our product candidates leverage the body’s natural pathways, providing us with the scientific insight to investigate their potential across multiple diseases.Roxadustat, our most advanced therapeutic, is an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, the enzyme that regulates HIF activity. By transiently inhibiting the enzyme, roxadustat induces the body’s natural coordinated process of producing red blood cells, increasing iron absorption, mobilization, and transport. We are developing roxadustat in partnership with AstraZeneca and Astellas for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

Bank Name FibroGen, Inc
Stock Exchange NASDAQ
Symbol FGEN
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman Mr. Thomas B. Neff
CEO Mr. Thomas B. Neff
Employees 423
Website www.fibrogen.com
Registered Year 1993

UpdateContent
UpdateContent
UpdateContent